Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology
12. August 2021 16:45 ET
|
Mustang Bio, Inc.
The exclusively licensed platform has potential application for any tumor target Preclinical development to continue at Mayo Clinic Mustang to file IND upon identification of a lead CAR construct ...
Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
02. August 2021 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive
17. Juni 2021 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio to Present at the Raymond James Human Health Innovation Conference
16. Juni 2021 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
11. Juni 2021 06:30 ET
|
Mustang Bio, Inc.
Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity 93% overall response rate and 67% complete response rate in...
Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
07. Juni 2021 08:00 ET
|
Mustang Bio, Inc.
Webinar to be held Tuesday, June 15, 2021, at 1:00 p.m. ET WORCESTER, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical...
Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
18. Mai 2021 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass. and DUARTE, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
14. Mai 2021 16:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress
12. Mai 2021 12:45 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy
10. Mai 2021 07:30 ET
|
Mustang Bio, Inc.
The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is...